$Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study$

Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study

Background: Sorafenib, a multi-kinase inhibitor, is approved for the treatment of patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). This study evaluated the efficacy and safety of sorafenib in real-world clinical practice and compared the results to those of the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Thyroid (New York, N.Y.) N.Y.), 2018-03, Vol.28 (3), p.34-348
Hauptverfasser:	Kim, Mijin, Kim, Tae Hyuk, Shin, Dong Yeob, Lim, Dong Jun, Kim, Eui Young, Kim, Won Bae, Chung, Jae Hoon, Shong, Young Kee, Kim, Bo Hyun, Kim, Won Gu
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Agents - therapeutic use Female Humans Male Middle Aged Progression-Free Survival Republic of Korea Retrospective Studies Sorafenib - therapeutic use Survival Analysis Survival Rate Tertiary Healthcare Thyroid Cancer and Nodules Thyroid Neoplasms - drug therapy Thyroid Neoplasms - mortality Thyroid Neoplasms - pathology Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!